# To Evaluate the Safety, Tolerability, and Pharmacokinetics/Pharmacodynamics of Erythropoietin

> **NCT01363934** · PHASE1 · COMPLETED · sponsor: **Green Cross Corporation** · enrollment: 100 (actual)

## Conditions studied

- Healthy Volunteer

## Interventions

- **DRUG:** GC1113
- **DRUG:** Darbepoetin alfa

## Key facts

- **NCT ID:** NCT01363934
- **Lead sponsor:** Green Cross Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-06
- **Primary completion:** 2012-07
- **Final completion:** 2012-07
- **Target enrollment:** 100 (ACTUAL)
- **Last updated:** 2012-07-19

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01363934

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01363934, "To Evaluate the Safety, Tolerability, and Pharmacokinetics/Pharmacodynamics of Erythropoietin". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01363934. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*